Home › Products › Infectious Disease › Kocitaf Tablet
Kocitaf Tablet
Salt Composition: DOLUTEGRAVIR,EMTRICITABINE,TENOFOVIR ALAFENAMIDE
- Manufacturer: MYLAN PHARMACEUTICALS PVT LTD
- Pack Size: 30 TABLET(s) IN A BOTTLE
- Dosage Form: TABLET
- Strength: 50MG+200MG+25MG
- Prescription Required
- Storage: Store this medication below 30°C Protect the medicine from light and excessive moisture. Keep the medicine out of reach of children and pets If you forgot to take the tablet, take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.
₹1800.00₹4115.00
Inclusive of all taxes
Product Introduction
Kocitaf Tablet is a combination antiretroviral medication containing dolutegravir, emtricitabine, and tenofovir alafenamide. Dolutegravir is an integrase strand transfer inhibitor (INSTI). Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI). Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI). This combination is used with other medicines to treat human immunodeficiency virus (HIV-1) infection in adults and adolescents aged 12 years who weigh at least 35 kg. The single tablet regimen reduces the number of pills patients must take daily, which simplifies treatment and improves medication adherence by helping individuals take their prescribed medication consistently as scheduled.
Do not take Kocitaf Tablet if you are allergic to it or any of its components. Regular HIV infection testing is necessary while using this medicine. Missing a dose increases the risk of HIV infection. This medicine does not prevent other sexually transmitted infections (STIs). Patients should inform their physician if they have liver problems or liver disease, including hepatitis, or kidney and bone problems. This medication is not recommended for children aged 11 years or under.
Uses
HIV infection
How it works
Kocitaf Tablet offers a highly effective and convenient treatment for HIV infection. It reduces viral load, maintains long-term viral suppression, and delays disease progression. A single-tablet regimen improves medication adherence. Additionally, it has an improved safety profile with a reduced risk of renal and bone toxicity.
How to Use
It is an orally available prescription drug. Your doctor will decide the dose and duration of Kocitaf Tablet based on the disease condition and other factors such as body weight and age. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with a glass of water. If you have difficulty in swallowing the tablet whole, you can split it in half after consulting with your doctor.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious Hepatitis B reactivation Increased risk of fracture Acute renal failure Common Headache Nausea Diarrhea Fatigue Insomnia
Expert Tips
If you are living with HIV or are at risk of contracting the virus, it is crucial to seek medical advice and follow a prescribed treatment plan. Antiretroviral therapy, such as the combination of Kocitaf Tablet, can significantly improve your health outcomes. However, it is essential to remember that medication adherence is key. Consistently taking your prescribed medication as directed by your healthcare provider and attending regular follow-up appointments will help ensure the effectiveness of the treatment and monitor your progress. Additionally, practicing safe sex, using clean needles, and taking preventive measures can significantly reduce the risk of HIV transmission. Remember to consult with healthcare professionals for personalized advice and guidance tailored to your specific needs and circumstances. Do not share needles or other items that may have blood or body fluids on them.
References
- Descovy 200 mg/25 mg film coated tablets - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk. Published April 2022. Accessed May 22, 2023. https://www.medicines.org.uk/emc/product/2108/smpc
- Emtricitabine / Tenofovir Alafenamide - Patient | NIH. clinicalinfo.hiv.gov. Published [February 27, 2023].[Accessed May 22, 2023]. https://clinicalinfo.hiv.gov/en/drugs/emtricitabine-tenofovir-alafenamide/patient#dr1
- KD Tripathi, Antiviral Drugs (Anti-retrovirus), Essentials of Medical Pharmacology, 8th Edition, 2019, 860-872.
- Gilead Sciences, Inc., US Food & Drug Administration, [Revised on Sep 2017] [Accessed on 22th Aug 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208215s005lbl.pdf
Safety Advice
Pregnancy: Consult your doctor There is limited information on the use of Kocitaf Tablet during pregnancy. Inform your physician if you are pregnant or planning to get pregnant during the treatment.
Lungs: Consult your doctor Kocitaf Tablet should be cautiously administered in patients with liver diseases. Dose adjustments are necessary. However, inform your physician of any liver diseases before initiating the therapy.
Breastfeeding: unsafe Breastfeeding is not recommended in patients taking Kocitaf Tablet because the medicine passes into the breast milk in small amounts and may harm your baby. Do not breastfeed during the treatment.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.